Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments.

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Renal Cell Carcinoma.

Januar 2025A team of Jülich scientists used a special RNA molecule to specifically attack and destroy glioblastoma cancer cells. The selectively ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success ...

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...